Note H - Segment Information

9 Months Ended

Mar. 31, 2025

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

H. Segment Information

Our business consists of two segments for financial reporting purposes. The two segments are identified as (i) private-label contract manufacturing, which primarily relates to the provision of private-label contract manufacturing services to companies that market and distribute nutritional supplements and other health care products, and (ii) patent and trademark licensing, which primarily includes direct raw material sales and royalty income from our license and supply agreements associated with the sale and use of beta-alanine under our CarnoSyn® and SR CarnoSyn® trademarks and our TriBsyn™ tradename

We evaluate performance of these segments based on a number of factors. The primary performance measures for each segment are net sales and income or loss from operations before the allocation of certain corporate level expenses. Operating income or loss for each segment does not include corporate general and administrative expenses, interest expense and other miscellaneous income and expense items. Corporate general and administrative expenses include, but are not limited to human resources, corporate legal, finance, information technology, and other corporate level related expenses, which are not allocated to any segment. Transfers of raw materials between segments are recorded at cost. The accounting policies of our segments are the same as those described in the summary of significant accounting policies in Note A above and in the consolidated financial statements included in our 2024 Annual Report.

Our operating results by business segment were as follows (in thousands):

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2025		2024		2025		2024
Net Sales
Private label contract manufacturing	$	27,075	$	22,479	$	90,021	$	77,718
Patent and trademark licensing		1,691		2,657		5,973		6,589
Total Net Sales	$	28,766	$	25,136	$	95,994	$	84,307

	Three Months Ended						Nine Months Ended
	March 31,						March 31,
	2025			2024			2025			2024
(Loss) Income from Operations
Private label contract manufacturing	$	(556	)	$	(1,007	)	$	(2,356	)	$	(2,367	)
Patent and trademark licensing		734			1,201		$	2,445			2,592
Income from operations of reportable segments		178			194			89			225
Corporate expenses not allocated to segments		(2,278	)		(2,146	)	$	(6,805	)		(6,234	)
Total Loss from Operations	$	(2,100	)	$	(1,952	)	$	(6,716	)	$	(6,009	)

	March 31,		June 30,
	2025		2024
Total Assets
Private-label contract manufacturing	$	118,002	$	127,786
Patent and trademark licensing		36,942		34,556
	$	154,944	$	162,342

Our private-label contract manufacturing products are sold both in the U.S. and in markets outside the U.S., including Europe, Canada, Australia, New Zealand, Mexico, and Asia. Our primary markets outside the U.S. are Europe and Asia. Our patent and trademark licensing activities are primarily based in the U.S.

Net sales by geographic region, based on the customers’ location, were as follows (in thousands):

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2025		2024		2025		2024
United States	$	18,250	$	15,457	$	59,635	$	56,990
Markets outside of the United States		10,516		9,679		36,359		27,317
Total	$	28,766	$	25,136	$	95,994	$	84,307

Products manufactured by our Swiss subsidiary ("NAIE") accounted for 84% of net sales in markets outside the U.S. for the three months ended March 31, 2025, and 82% for the nine months ended March 31, 2025. Products manufactured by NAIE accounted for 68% of net sales in markets outside the U.S. for the three months ended March 31, 2024, and 76% for the nine months ended March 31, 2024

Long-lived assets by geographic region, based on the location of the company's facilities at which they were located or made, were as follows (in thousands):

	March 31, 2025		June 30, 2024
United States	$	76,302	$	78,146
Europe		15,944		17,602
Total Long-Lived Assets	$	92,246	$	95,748

Total assets by geographic region, based on the location of the Company's facilities at which they were located or made, were as follows (in thousands):

	March 31, 2025		June 30, 2024
United States	$	112,646	$	118,878
Europe		42,298		43,464
Total Assets	$	154,944	$	162,342

Capital expenditures by geographic region, based on the location of the Company's facilities at which they were located or made, were as follows (in thousands):

	Nine Months Ended
	March 31,
	2025		2024
United States	$	1,928	$	1,801
Europe		231		182
Total Capital Expenditures	$	2,159	$	1,983